Pharmaceuticals & Therapeutics

With a 2026 launch looming, Nuvalent adds a proven oncology dealmaker to its board, signaling a strategic pivot from R&D to market assault.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Regulatory filings reveal Balyasny Asset Management's strategic trades in Avadel Pharma, offering a glimpse into the high-stakes bidding war with Alkermes.

New data shows Kazia's paxalisib dismantles metastatic drivers and reignites immunity, signaling a strategic disruption in advanced breast cancer treatment.

MediWound's burn treatment now prevents traumatic tattoos from blasts and accidents, signaling a major strategic expansion and a new era in trauma care.

Beyond a simple FDA approval, Amneal's entry into the epinephrine vial market is a calculated move to fix a broken supply chain and drive growth.

A prestigious Yale recognition for board member Dr. Curtis Patton bolsters Tevogen's credibility as it advances its AI and T-cell platforms.

A regulatory filing from Balyasny Asset Management reveals intense investor activity as a bidding war for narcolepsy drugmaker Avadel heats up.

Regenerative Patch Technologies advances its stem cell therapy for dry AMD, signaling a potential shift from merely slowing blindness to actively improving vision.

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

A fierce bidding war for Avadel Pharmaceuticals reveals the high value of its key drug, as filings from giants like State Street highlight M&A transparency.

A new patent for its lead cancer drug in Japan is more than a legal win; it's a strategic move to secure a future market into the 2040s.

Dr. Timothy Lubenow's move from a top university to a community clinic highlights a trend that's making advanced medical care more accessible.

Animal health giant Elanco is restructuring its global footprint, betting its future on a U.S.-centric innovation pipeline and blockbuster pet health drugs.

With stellar clinical data for its TERN-701 drug, Terns is raising massive capital to challenge Novartis and reshape the multi-billion-dollar CML market.

Guangdong Jiaying Pharma is leveraging its unique Hakka heritage to enter the global market. But can ancient wisdom navigate modern regulatory and corporate hurdles?

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Beyond the active ingredient, a silent revolution in formulation technology is unlocking new frontiers in health, from clean labels to personalized nutrition.